MARKET

RIGL

RIGL

Rigel Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.720
+0.060
+1.64%
Opening 10:49 04/23 EDT
OPEN
3.700
PREV CLOSE
3.660
HIGH
3.775
LOW
3.640
VOLUME
458.00K
TURNOVER
--
52 WEEK HIGH
5.50
52 WEEK LOW
1.490
MARKET CAP
632.85M
P/E (TTM)
-21.1364
1D
5D
1M
3M
1Y
5Y
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Profit Outlook
We feel now is a pretty good time to analyse Rigel Pharmaceuticals, Inc.'s ( NASDAQ:RIGL ) business as it appears the...
Simply Wall St. · 3d ago
Is an EUA for Rigel’s COVID-19 Treatment in the Cards? Analyst Weighs In
Several coronavirus stocks were on the move this week in reaction to the CDC (Centers for Disease Control and Prevention) and the FDA both suggesting a halt to the use of Johnson & Johnson's COVID-19 vaccine. The recommendation followed the news that some ...
TipRanks · 6d ago
Company News for Apr 14, 2021
Companies in the news are: MFNC, NVCR, RIGL, VTVT
Zacks · 04/14 13:04
8-K: RIGEL PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- 0001034842 false 0001034842 2021-04-13 2021-04-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/14 03:33
NovoCure, vTv Therapeutics leads healthcare gainers; Avenue Therapeutics, AdaptHealth among major losers
Gainers: NovoCure (NVCR) +45%, vTv Therapeutics (VTVT) +28%, Rigel Pharmaceuticals (RIGL) +15%, Zai Lab (ZLAB) +14%, Vallon Pharmaceuticals (VLON) +10%.Losers: Avenue Therapeutics (ATXI) -17%, AdaptHealth (AHCO) -17%, Brooklyn ImmunoTherapeutics (BTX) -16%...
Seekingalpha · 04/13 15:04
DJ Rigel Pharmaceuticals Up 12% After Covid-19 Trial Meets Safety Goal
Dow Jones · 04/13 14:45
Rigel (RIGL) Receives a Rating Update from a Top Analyst
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (RIGL), with a price target of $11.00. The company's
SmarterAnalyst · 04/13 14:25
Rigel Pharmaceuticals Granted U.S. Patent Titled 'RIP1 inhibitory compounds and methods for making and using the same'
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=10975064.PN.&OS=PN/10975064&RS=PN/10975064
Benzinga · 04/13 14:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RIGL. Analyze the recent business situations of Rigel Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RIGL stock price target is 8.50 with a high estimate of 11.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 212
Institutional Holdings: 154.76M
% Owned: 90.97%
Shares Outstanding: 170.12M
TypeInstitutionsShares
Increased
43
7.47M
New
26
4.76M
Decreased
52
10.86M
Sold Out
15
1.20M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.06%
Pharmaceuticals & Medical Research
+0.44%
Key Executives
President/Chief Executive Officer/Director
Raul Rodriguez
Chief Financial Officer/Executive Vice President
Dean Schorno
Executive Vice President/General Counsel/Secretary
Dolly Vance
Executive Vice President
Wolfgang Dummer
Executive Vice President
David Santos
Senior Vice President
Esteban Masuda
Independent Director
Bradford Goodwin
Independent Director
Keith Katkin
Independent Director
Brian Kotzin
Independent Director
Gregg Lapointe
Independent Director
Gary Lyons
Independent Director
Walter Moos
Independent Director
Jane Wasman
No Data
About RIGL
Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.

Webull offers kinds of Rigel Pharmaceuticals, Inc. stock information, including NASDAQ:RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.